Innoviva (INVA) investor relations material

Executive summary

• Diversified biopharma with a core royalty portfolio, critical care/infectious disease platform, and strategic healthcare investments.

• Transitioned from a pure-play royalty business to a diversified operator with multiple marketed products and significant healthcare assets.

• Achieved total revenue of $119.6 million in Q2 2026, up 19% year-over-year, driven by strong IST net product sales and stable royalty income.

• Focused on maximizing respiratory royalties, commercializing critical care products, and optimizing capital allocation.

• Launched Nortiva Bio, a wholly owned subsidiary focused on long-acting oral drug delivery technology.

Financial highlights

• Total revenue for Q2 2026 was $119.6M, up 19% year-over-year; net product sales grew 46% to $51.8M.

• Net loss of $83.4M for Q2 2026, primarily due to a $161M unfavorable change in fair value of equity and long-term investments, mainly Armata.

• Cash and cash equivalents stood at $570.4M; royalty and net product sales receivables increased 25% year-over-year to $110.6M.

• Income from operations was $50.9M, up from $48.8M in Q2 2025.

• Royalty revenue was $59.8M, a 2% sequential increase from Q1 2026.

Outlook and guidance

• Management expects continued growth in net product sales and ongoing investment in strategic healthcare assets.

• On track to achieve at least $150M in IST U.S. net product sales for 2026.

• Cash resources are considered sufficient for at least the next 12 months, supporting operations, debt service, and share repurchases.